Fan Jie, Ma Li-Jie, Xia Shu-Jie, Yu Long, Fu Qiang, Wu Chao-Qun, Huang Xing-Hua, Jiang Jian-Ming, Tang Xiao-Da
Department of Urology, Shanghai Jiaotong University, Shanghai First People's Hospital, 85 Wujin Road, 200080 Shanghai, P.R. China.
J Cancer Res Clin Oncol. 2005 Mar;131(3):157-62. doi: 10.1007/s00432-004-0638-8. Epub 2004 Dec 14.
Bladder carcinoma is the most common urological malignancy in China. Gene mutation may be one of causes of carcinogenesis in the cancer. We therefore investigated the mRNA expression of RTKN gene in clinic malignant bladder carcinoma and explored the relationship between the novel gene and the cancer.
Total RNA was extracted from 33 surgically resected specimens of bladder carcinoma and 19 specimens of tumor-free bladder tissues. After the optimal reverse-transcription polymerase chain reaction condition was established, the mRNA expression levels of the RTKN gene in the lesions and tumor-free bladder tissues were examined semiquantitatively, and the relationships between expression levels of RTKN and clinical pathological features were analyzed.
The expression of RTKN gene mRNA in 33 human bladder carcinoma tissues was significantly higher than that in 19 human tumor-free bladder tissues (0.937+/-0.103 vs. 0.350+/-0.082). The average ratio of RTKN expression in neoplasms to that in tumor-free bladder tissues was 0.350+/-0.164. Based on this ratio the 33 patients were divided into three groups: a down-regulated expression group (n=2), an up-regulated expression group (n=22), and an unchanged group (n=9). Although the chi(2) test demonstrated a statistically nonsignificant differences in RTKN expression between tumor stages Ta, T(1), and T(2) overall in the 33 human bladder carcinoma, the t test showed that there were statistically significant differences between solitary and multiple tumors, between the paired group aged younger or older than 70 years in 27 de novo bladder carcinoma patients, and between the groups with tumor larger or smaller than 2.25 cm(3).
These results suggest that the RTKN gene is involved in bladder carcinogenesis and progression in bladder carcinoma, indicating that RTKN gene could be a molecular target in cancer therapy.
膀胱癌是中国最常见的泌尿系统恶性肿瘤。基因突变可能是该癌症致癌的原因之一。因此，我们研究了RTKN基因在临床恶性膀胱癌中的mRNA表达，并探讨了该新基因与癌症之间的关系。
从33例手术切除的膀胱癌标本和19例无肿瘤膀胱组织标本中提取总RNA。在建立最佳逆转录聚合酶链反应条件后，对病变组织和无肿瘤膀胱组织中RTKN基因的mRNA表达水平进行半定量检测，并分析RTKN表达水平与临床病理特征之间的关系。
33例人膀胱癌组织中RTKN基因mRNA的表达明显高于19例人无肿瘤膀胱组织（0.937±0.103对0.350±0.082）。肿瘤组织中RTKN表达与无肿瘤膀胱组织中RTKN表达的平均比值为0.350±0.164。根据该比值，将33例患者分为三组：表达下调组（n = 2）、表达上调组（n = 22）和无变化组（n = 9）。虽然卡方检验显示33例人膀胱癌中Ta、T1和T2期肿瘤的RTKN表达总体差异无统计学意义，但t检验显示，单发与多发肿瘤之间、27例初发性膀胱癌患者中年龄小于或大于70岁的配对组之间以及肿瘤体积大于或小于2.25 cm³的组之间存在统计学显著差异。
这些结果表明RTKN基因参与膀胱癌的发生和进展，提示RTKN基因可能是癌症治疗的分子靶点。
